News and updates — Page 9 of 15 — German Market Access

G-BA defines 4 strict requirements on cefiderocol use to protect its “reserve antibiotics” status

Currently, reserve antibiotics are excluded from a benefit assessment by the G-BA. The G-BA decides whether to accept a new antibiotic onto the

During the pandemic, the G-BA introduced special regulations for hospital care. Based on their good experiences with these, the G-BA has now

From medical devices last week, we are moving back to digital health applications (DiGAs), and how clinician fees are set for these

Hi again! This week I am switching it up a bit, and look at medical devices, particularly the EU regulation for medical

In this post, I’m following up on the key points on the real-world evidence (RWE) data collection in Germany with an IQWiG

In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since

Welcome to another post on possible changes and the plans of the German Health Minister for the healthcare system in the next

Hello again! Today, I’m completing the series on quality assurance today with quality contracts for hospitals in Germany. In the next post,

Welcome again! We are extending the short excursion to quality assurance today with a look at minimum case numbers in Germany. In

Welcome to the second post in the quality assurance series, focusing on the hot topic of ATMPs! Next week, I’ll be focusing